Celldex Named Top Biotech Pick by Guggenheim on Urticaria Drug's Potential

Guggenheim Securities has reaffirmed Celldex Therapeutics (CLDX) as its top biotechnology stock pick, citing the significant commercial potential of its lead drug candidate, barzolvolimab, ahead of crucial late-stage clinical trial data. The firm believes the market is underestimating the drug's opportunity in the chronic urticaria market.

The Analyst's Thesis

In a note to clients, Guggenheim reiterated a "Buy" rating on Celldex shares and maintained its $100 price target. The firm's positive outlook is centered on barzolvolimab, which it estimates could generate approximately $3 billion in peak global sales.

Analysts see a potential upside to between $3 billion and $5 billion if the upcoming Phase III results replicate the strong efficacy observed in Phase II studies. This higher-end forecast also depends on the drug successfully expanding into additional indications. Guggenheim stated that barzolvolimab's efficacy, durability, and benefits in difficult-to-treat patients could support premium pricing.

A Growing Market Opportunity

Guggenheim's analysis highlights the large, underserved market for chronic spontaneous urticaria, a condition characterized by hives. The brokerage estimates that approximately 580,000 patients in the U.S. with moderate-to-severe cases are inadequately controlled by standard antihistamine treatments.

Ad

Furthermore, the penetration of biologic therapies in this market is only about 20%, according to the firm. This leaves substantial room for growth and suggests a significant opportunity for new, more effective therapies to gain wider adoption.

Key Catalysts Ahead

Investors are closely watching for several upcoming clinical milestones that could significantly impact Celldex's valuation. Guggenheim identified several key catalysts on the horizon:

• Topline data from two Phase III trials, EMBARQ-CSU1 and CSU2, is expected in September or October.
• Phase II data for barzolvolimab in atopic dermatitis is anticipated later this year.
• Additional clinical updates for another pipeline candidate, CDX-622.